- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Nivolumab (non-squamous nsclc) – March 2016
Nivolumab: 40mg in 4ml (10mg/mL concentrate for IV infusion) 100mg in 10mL (10mg/mL concentrate for IV infusion), Opdivo®
Last updated
15 July 2016